Skip to content

Study · Randomized controlled trial · n = 10 · 1998

5 results

Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study.

Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N

The Journal of urology1 Aug 1998Cited by 115 (Europe PMC)

PMID9679884 (opens in a new tab)DOI10.1016/s0022-5347(01)62903-3 (opens in a new tab)PepBankPUB-09679884
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In men with psychogenic erectile dysfunction, clinically apparent erections developed in 8 of 10 men treated with Melanotan II.

    In plain wordsIn men with erectile dysfunction of no known organic cause, 8 of 10 men treated with Melanotan II had clear erections.

    Peptide
    Melanotan II
    Outcome
    Not applicableClinically apparent erections
    Study

    n = 10

    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    0.025 mg/kgAs given in this study (human).

    Measurements

    men with erections
    8 of 10 men
    Melanotan-II

    Source sentences

    Summary
    In 8 of 10 men treated with Melanotan-II clinically apparent erections developed.
    2 context sentences
    Summary · context
    Ten men with erectile dysfunction of no known organic cause were entered in a double-blind, placebo controlled crossover study in which the erectogenic properties of Melanotan-II and a vehicle placebo were compared using real-time RigiScan monitoring.
    Summary · context
    Melanotan-II is a potent initiator of erections in men with psychogenic erectile dysfunction and has manageable side effects at a dose of 0.025 mg./kg.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In men with psychogenic erectile dysfunction, mean duration of tip rigidity above 80% was 38.0 minutes with Melanotan II versus 3.0 with placebo.

    In plain wordsIn men with erectile dysfunction, Melanotan II gave longer firm erections than placebo (38.0 minutes versus 3.0 minutes).

    Peptide
    Melanotan II
    Outcome
    IncreaseDuration of tip rigidity above 80%
    Study

    n = 10

    Comparator
    Placebo
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    0.025 mg/kgAs given in this study (human).

    Measurements

    mean duration of tip rigidity >80%
    38 minutes
    Melanotan-II
    mean duration of tip rigidity >80%
    3 minutes
    placebo
    P value
    0.0045
    between groups

    Source sentences

    Summary
    Mean duration of tip rigidity greater than 80% was 38.0 minutes with Melanotan-II and 3.0 with placebo (p=0.0045).
    2 context sentences
    Summary · context
    Ten men with erectile dysfunction of no known organic cause were entered in a double-blind, placebo controlled crossover study in which the erectogenic properties of Melanotan-II and a vehicle placebo were compared using real-time RigiScan monitoring.
    Summary · context
    Melanotan-II is a potent initiator of erections in men with psychogenic erectile dysfunction and has manageable side effects at a dose of 0.025 mg./kg.
  3. 03HumanRandomized controlled trialSafety outcome

    In men with psychogenic erectile dysfunction, transient nausea was reported more frequently after Melanotan II injections than after placebo, and none required treatment.

    In plain wordsIn men with erectile dysfunction, short-lived nausea happened more often after Melanotan II than after placebo. None needed treatment.

    Peptide
    Melanotan II
    Outcome
    IncreaseNausea
    Study

    n = 10

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.025 mg/kgAs given in this study (human).

    Source sentences

    Summary
    Transient side effects of nausea, stretching and yawning, and decreased appetite were reported more frequently after injections of Melanotan-II than placebo but none required treatment.
    2 context sentences
    Summary · context
    Ten men with erectile dysfunction of no known organic cause were entered in a double-blind, placebo controlled crossover study in which the erectogenic properties of Melanotan-II and a vehicle placebo were compared using real-time RigiScan monitoring.
    Summary · context
    Melanotan-II is a potent initiator of erections in men with psychogenic erectile dysfunction and has manageable side effects at a dose of 0.025 mg./kg.
  4. 04HumanRandomized controlled trialSafety outcome

    In men with psychogenic erectile dysfunction, transient stretching and yawning were reported more frequently after Melanotan II injections than after placebo, and none required treatment.

    In plain wordsIn men with erectile dysfunction, short-lived stretching and yawning happened more often after Melanotan II than after placebo. None needed treatment.

    Peptide
    Melanotan II
    Outcome
    IncreaseStretching and yawning
    Study

    n = 10

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    0.025 mg/kgAs given in this study (human).

    Source sentences

    Summary
    Transient side effects of nausea, stretching and yawning, and decreased appetite were reported more frequently after injections of Melanotan-II than placebo but none required treatment.
    2 context sentences
    Summary · context
    Ten men with erectile dysfunction of no known organic cause were entered in a double-blind, placebo controlled crossover study in which the erectogenic properties of Melanotan-II and a vehicle placebo were compared using real-time RigiScan monitoring.
    Summary · context
    Melanotan-II is a potent initiator of erections in men with psychogenic erectile dysfunction and has manageable side effects at a dose of 0.025 mg./kg.
  5. 05HumanRandomized controlled trialSafety outcome

    In men with psychogenic erectile dysfunction, transient decreased appetite was reported more frequently after Melanotan II injections than after placebo, and none required treatment.

    In plain wordsIn men with erectile dysfunction, short-lived loss of appetite happened more often after Melanotan II than after placebo. None needed treatment.

    Peptide
    Melanotan II
    Outcome
    IncreaseDecreased appetite
    Study

    n = 10

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    0.025 mg/kgAs given in this study (human).

    Source sentences

    Summary
    Transient side effects of nausea, stretching and yawning, and decreased appetite were reported more frequently after injections of Melanotan-II than placebo but none required treatment.
    2 context sentences
    Summary · context
    Ten men with erectile dysfunction of no known organic cause were entered in a double-blind, placebo controlled crossover study in which the erectogenic properties of Melanotan-II and a vehicle placebo were compared using real-time RigiScan monitoring.
    Summary · context
    Melanotan-II is a potent initiator of erections in men with psychogenic erectile dysfunction and has manageable side effects at a dose of 0.025 mg./kg.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.